Natixis Advisors LLC Has $156.76 Million Stock Holdings in Sanofi $SNY

Natixis Advisors LLC raised its holdings in Sanofi (NASDAQ:SNY) by 3.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,234,911 shares of the company’s stock after purchasing an additional 121,530 shares during the quarter. Natixis Advisors LLC owned 0.13% of Sanofi worth $156,764,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Advisory Services Network LLC boosted its holdings in shares of Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after purchasing an additional 210 shares in the last quarter. Waterfront Wealth Inc. boosted its holdings in shares of Sanofi by 0.4% in the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after purchasing an additional 214 shares in the last quarter. Savant Capital LLC boosted its holdings in shares of Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after purchasing an additional 225 shares in the last quarter. HighPoint Advisor Group LLC boosted its holdings in shares of Sanofi by 2.3% during the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after acquiring an additional 226 shares in the last quarter. Finally, Wesbanco Bank Inc. boosted its holdings in shares of Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after acquiring an additional 230 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of several recent research reports. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Monday, April 20th. Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $51.00.

Sanofi Stock Down 1.6%

Shares of NASDAQ:SNY opened at $42.96 on Tuesday. The company has a market capitalization of $104.15 billion, a price-to-earnings ratio of 12.00, a P/E/G ratio of 1.08 and a beta of 0.34. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The business’s 50-day moving average is $45.57 and its 200-day moving average is $46.96. Sanofi has a 1 year low of $42.33 and a 1 year high of $52.68.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be paid a $2.4225 dividend. The ex-dividend date of this dividend is Monday, May 4th. This represents a dividend yield of 559.0%. This is a positive change from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.